Sera Prognostics Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000

Reuters

Mar 19

<a href="https://laohu8.com/S/SERA">Sera Prognostics</a> Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000

Sera Prognostics published a press release reporting fourth-quarter and full-year 2025 financial results. Q4 revenue was USD 10,000, down 58.33%, while net loss narrowed to USD 7.88 million. FY 2025 revenue was USD 81,000, while net loss narrowed to USD 31.93 million. FY 2025 R&D expense fell 10.55% to USD 13.17 million due to lower clinical study costs following completion of the PRIME study, while SG&A rose 6.39% to USD 23.3 million on targeted commercial activities and strategic headcount additions. Cash, cash equivalents and available-for-sale securities totaled USD 95.8 million at year-end, and CEO Zhenya Lindgardt said the company is focused on converting PRIME study evidence into broader adoption and payer coverage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA12849) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620264737"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620264737\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620264737?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620264737","market":"fut","top_or_hot":-1,"title":"Sera Prognostics Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SERA\">Sera Prognostics</a> Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sera Prognostics published a press release reporting fourth-quarter and full-year 2025 financial results. Q4 revenue was USD 10,000, down 58.33%, while net loss narrowed to USD 7.88 million. FY 2025 revenue was USD 81,000, while net loss narrowed to USD 31.93 million. FY 2025 R&amp;D expense fell 10.55% to USD 13.17 million due to lower clinical study costs following completion of the PRIME study, while SG&amp;A rose 6.39% to USD 23.3 million on targeted commercial activities and strategic headcount additions. Cash, cash equivalents and available-for-sale securities totaled USD 95.8 million at year-end, and CEO Zhenya Lindgardt said the company is focused on converting PRIME study evidence into broader adoption and payer coverage.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA12849) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sera Prognostics Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSera Prognostics Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SERA\">Sera Prognostics</a> Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sera Prognostics published a press release reporting fourth-quarter and full-year 2025 financial results. Q4 revenue was USD 10,000, down 58.33%, while net loss narrowed to USD 7.88 million. FY 2025 revenue was USD 81,000, while net loss narrowed to USD 31.93 million. FY 2025 R&amp;D expense fell 10.55% to USD 13.17 million due to lower clinical study costs following completion of the PRIME study, while SG&amp;A rose 6.39% to USD 23.3 million on targeted commercial activities and strategic headcount additions. Cash, cash equivalents and available-for-sale securities totaled USD 95.8 million at year-end, and CEO Zhenya Lindgardt said the company is focused on converting PRIME study evidence into broader adoption and payer coverage.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA12849) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SERA","symbol_name":"Sera Prognostics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1lk7ss:1","article_id":"2620264737","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620264737","pubTimestamp":1773864367,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sera Prognostics published a press release reporting fourth-quarter and full-year 2025 financial results. Q4 revenue was USD 10,000, down 58.33%, while net loss narrowed to USD 7.88 million. FY 2025 revenue was USD 81,000, while net loss narrowed to USD 31.93 million. FY 2025 R&D expense fell 10.55% to USD 13.17 million due to lower clinical study costs following completion of the PRIME study, while SG&A rose 6.39% to USD 23.3 million on targeted commercial activities and strategic headcount additions. Cash, cash equivalents and available-for-sale securities totaled USD 95.8 million at year-end, and CEO Zhenya Lindgardt said the company is focused on converting PRIME study evidence into broader adoption and payer coverage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SERA":"Sera Prognostics, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Sera Prognostics第四季度净亏损收窄8.13%至788万美元，收入下降58.33%至10,000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SERA":0.9},"content_text":"Sera Prognostics Q4 net loss narrows 8.13% to USD 7.88 million as revenue falls 58.33% to USD 10,000\n    \n\n        Sera Prognostics published a press release reporting fourth-quarter and full-year 2025 financial results. Q4 revenue was USD 10,000, down 58.33%, while net loss narrowed to USD 7.88 million. FY 2025 revenue was USD 81,000, while net loss narrowed to USD 31.93 million. FY 2025 R&D expense fell 10.55% to USD 13.17 million due to lower clinical study costs following completion of the PRIME study, while SG&A rose 6.39% to USD 23.3 million on targeted commercial activities and strategic headcount additions. Cash, cash equivalents and available-for-sale securities totaled USD 95.8 million at year-end, and CEO Zhenya Lindgardt said the company is focused on converting PRIME study evidence into broader adoption and payer coverage.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA12849) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}